When is second allogeneic HSCT for relapse of acute leukaemia an option? (Q86865002)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26642335 AND SRC:MED&resulttype=core&format=json

2 March 2020

title

When is second allogeneic HSCT for relapse of acute leukaemia an option? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26642335 AND SRC:MED&resulttype=core&format=json

2 March 2020

author

Maximilian Christopeit

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26642335 AND SRC:MED&resulttype=core&format=json

2 March 2020

publication date

7 December 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26642335 AND SRC:MED&resulttype=core&format=json

Bone Marrow Transplantation

2 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26642335 AND SRC:MED&resulttype=core&format=json

2 March 2020

volume

51

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26642335 AND SRC:MED&resulttype=core&format=json

2 March 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26642335 AND SRC:MED&resulttype=core&format=json

2 March 2020

page(s)

184-185

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26642335 AND SRC:MED&resulttype=core&format=json

Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of ⩾10 years

2 March 2020

cites work

1 reference

12 December 2020

NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantatio

1 reference

12 December 2020

Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant

1 reference

12 December 2020

Reduced-intensity conditioning with fludarabine and thiotepa for second allogeneic transplantation of relapsed patients with AML

1 reference

12 December 2020

Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT.

1 reference

12 December 2020

Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation

1 reference

12 December 2020

Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change

1 reference

12 December 2020

Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

1 reference

12 December 2020

Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions--a retrospective multicenter analysis from the German Cooperative Transplant Study Gro

1 reference

12 December 2020

Second allogeneic bone marrow transplantation in acute leukemia: a multicenter study from the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO)

1 reference

12 December 2020

Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant.

1 reference

12 December 2020

EBMT Risk Score Predicts Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Who Have Failed a Previous Transplantation Procedure

1 reference

12 December 2020

Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation

1 reference

12 December 2020

Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation

1 reference

12 December 2020

Management of relapse after allo-SCT for AML and the role of second transplantation.

1 reference

12 December 2020

Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes.

1 reference

12 December 2020

Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute

1 reference

12 December 2020